Pacira Pharma (PCRX) Tops Q1 EPS by 3c ; Offers Guidance

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $168.92 million versus the consensus estimate of $175.6 million.

GUIDANCE:

Pacira Pharma sees FY2025 revenue of $725-765 million, versus the consensus of $752.9 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance